Does Blue Cross Blue Shield Cover Jardiance?

How BCBS Formulary Coverage Works for Jardiance

Blue Cross Blue Shield is not a single insurer. It is a federation of 34 independently operated companies, each maintaining its own drug formulary and coverage policies. That structural detail matters because your BCBS card from Michigan applies different rules than one issued in Texas or Florida.

Most BCBS affiliates place Jardiance on their formulary as a covered brand-name medication, but the specific tier assignment varies. A 2023 analysis of commercial formularies found that SGLT2 inhibitors appeared on approximately 95% of major insurer formularies, though tier placement differed significantly across plans [1]. Tier 3 placement (preferred brand) generally means a copay of $35 to $75 per month. Tier 4 (non-preferred brand) pushes that range to $75 to $150 or higher.

Your plan's Summary of Benefits and Coverage (SBC) document lists the exact tier. You can also search your affiliate's online formulary tool by entering "empagliflozin" or "Jardiance" directly. BCBS Federal Employee Program (FEP) plans, which cover roughly 5.3 million federal workers and dependents, list Jardiance on the preferred brand tier with a standard copay structure [2].

Why BCBS Plans Cover Jardiance: The Clinical Evidence

BCBS affiliates base formulary decisions on clinical efficacy, safety data, and cost-effectiveness evaluations. Jardiance has accumulated a strong evidence base across three distinct indications, which supports its formulary inclusion.

The EMPA-REG OUTCOME trial (N=7,020) demonstrated that empagliflozin reduced cardiovascular death by 38% in patients with type 2 diabetes and established cardiovascular disease compared to placebo (HR 0.62; 95% CI 0.49 to 0.77; P<0.001) [3]. This trial reshaped prescribing patterns and prompted the American Diabetes Association (ADA) to recommend SGLT2 inhibitors as preferred second-line agents for patients with atherosclerotic cardiovascular disease [4].

The EMPEROR-Preserved trial (N=5,988) extended empagliflozin's reach into heart failure with preserved ejection fraction (HFpEF), showing a 21% reduction in the combined risk of cardiovascular death or hospitalization for heart failure [5]. The FDA granted Jardiance expanded approval for heart failure regardless of ejection fraction in February 2022.

Most recently, the EMPA-KIDNEY trial (N=6,609) showed that empagliflozin reduced kidney disease progression or cardiovascular death by 28% in patients with chronic kidney disease (HR 0.72; 95% CI 0.64 to 0.82), leading to the trial's early termination for overwhelming efficacy [6]. These data collectively give BCBS pharmacy and therapeutics committees strong justification to maintain formulary coverage.

Prior Authorization Requirements

Prior authorization (PA) is the most common barrier patients encounter when filling a Jardiance prescription through BCBS. PA requires your prescriber to submit clinical documentation proving the medication is medically necessary before the pharmacy can dispense it.

Typical BCBS prior authorization criteria for Jardiance include:

• A confirmed diagnosis of type 2 diabetes mellitus, heart failure, or chronic kidney disease
• Documentation of an adequate trial (usually 90 days) of metformin, unless contraindicated
• Current hemoglobin A1c level (for diabetes indication)
• Evidence that the patient has not responded to or cannot tolerate a sulfonylurea or DPP-4 inhibitor (some plans only)

PA turnaround time is generally 48 to 72 hours for standard requests. Urgent requests, such as when a patient is transitioning from hospital discharge, can be expedited within 24 hours. The ADA's 2024 Standards of Care explicitly discourage step therapy requirements that delay SGLT2 inhibitor access for patients with cardiovascular or renal comorbidities, noting that "delays in initiating evidence-based cardiorenal protective therapy may result in preventable morbidity" [4].

If your prescriber submits a PA and it gets denied, the insurer must provide a written explanation. You have the right to appeal.

Step Therapy: What BCBS May Require Before Approving Jardiance

Step therapy protocols require patients to try (and fail or show intolerance to) one or more lower-cost medications before the plan approves a higher-tier drug. For Jardiance, the most common step therapy sequence across BCBS affiliates looks like this:

Step 1: Metformin (generic, Tier 1). The ADA recommends metformin as first-line pharmacotherapy for most adults with type 2 diabetes, and its generic status makes it the default starting point [4].

Step 2: A sulfonylurea (glipizide, glimepiride) or a DPP-4 inhibitor (sitagliptin). These are typically Tier 1 or Tier 2 generics.

Step 3: Jardiance or another SGLT2 inhibitor becomes approvable after documented failure of, intolerance to, or contraindication for Step 1 and/or Step 2 agents.

A key exception exists. Patients with established atherosclerotic cardiovascular disease (ASCVD), heart failure, or chronic kidney disease may qualify for a step therapy override. The EMPA-REG OUTCOME and EMPEROR trials established empagliflozin's organ-protective benefits independent of glucose lowering [3][5]. Many BCBS affiliates now allow direct access to SGLT2 inhibitors for these higher-risk patients without requiring metformin failure first, aligning with ADA/American Heart Association joint guidance [7].

Your physician can request a step therapy exception by submitting clinical notes documenting the relevant comorbidity.

How Much Will You Pay Out of Pocket?

Your actual cost depends on four variables: plan tier, deductible status, copay vs. coinsurance design, and whether you use the manufacturer coupon.

Before deductible is met: You pay the full negotiated rate, which can range from $400 to $620 per month depending on your BCBS affiliate's pharmacy benefit manager (PBM) contract. Some BCBS plans use an accumulator adjustment program that prevents manufacturer coupons from counting toward your deductible.

After deductible, Tier 3 copay: Typically $35 to $75 per 30-day supply.

After deductible, Tier 4 coinsurance: Some plans charge 25% to 50% coinsurance instead of a flat copay, which could mean $100 to $200+ monthly.

With manufacturer savings card: Boehringer Ingelheim offers an empagliflozin savings card that reduces out-of-pocket costs to as low as $10 per month for eligible commercially insured patients. The card covers up to $300 per 30-day fill. Patients with government insurance (Medicare, Medicaid, Tricare) are not eligible for this program [8].

Medicare Part D plans operated by BCBS: Jardiance is covered under most Medicare Part D formularies. Under the Inflation Reduction Act provisions that took effect in 2025, Medicare beneficiaries pay a maximum of $2,000 annually in total out-of-pocket prescription drug costs, which significantly reduces the financial burden for brand-name medications like Jardiance [9].

BCBS Medicare Advantage vs. Commercial Plans

Coverage rules differ substantially between BCBS commercial (employer-sponsored or individual marketplace) plans and BCBS Medicare Advantage plans. The distinction matters because over 9 million Americans are enrolled in a BCBS Medicare Advantage product.

Commercial plans set their own formulary tiers and PA criteria with minimal federal regulation beyond essential health benefit mandates. Medicare Advantage plans must cover all drugs in the six protected classes and comply with CMS formulary adequacy standards, though diabetes medications outside the protected classes (which include antidiabetics) must still meet CMS coverage criteria [9].

In practical terms, BCBS Medicare Advantage plans almost universally cover Jardiance because antidiabetic agents fall within a CMS-protected class. The PA requirements tend to be less restrictive than commercial plan criteria. The $2,000 annual out-of-pocket cap under the Inflation Reduction Act applies to all Medicare Part D plans, including those administered by BCBS affiliates [9].

BCBS FEP (Federal Employee Program) plans maintain a single national formulary, making coverage more predictable than state-by-state commercial products. The 2025 FEP formulary lists Jardiance as a Tier 2 preferred brand with a copay of $60 for a 30-day retail fill and $120 for a 90-day mail-order supply [2].

What to Do If BCBS Denies Jardiance Coverage

A coverage denial is not the final word. BCBS affiliates are required by state and federal law to provide a formal appeals process. Data from the Kaiser Family Foundation show that approximately 40% to 60% of prescription drug denials are overturned on first-level appeal when supported by clinical documentation [10].

Step 1: Understand the denial reason. Read the Explanation of Benefits (EOB) letter carefully. Common denial codes include "not medically necessary," "step therapy required," or "non-formulary."

Step 2: File a first-level internal appeal. Your prescriber should submit a letter of medical necessity that includes your diagnosis, relevant lab values (A1c, eGFR, BNP), prior medication trials and outcomes, and citations to clinical guidelines supporting empagliflozin use. Reference the ADA Standards of Care and the relevant landmark trial (EMPA-REG OUTCOME for ASCVD, EMPEROR-Preserved/Reduced for heart failure, EMPA-KIDNEY for CKD) [3][4][5][6].

Step 3: Request an external review if the internal appeal fails. Under the Affordable Care Act, you have the right to an independent external review by a third-party organization. The external reviewer's decision is binding on the insurer.

Step 4: Contact your state insurance commissioner. If you believe the denial violates state insurance regulations, filing a complaint with your state's department of insurance can prompt an investigation.

The entire internal appeal process typically takes 30 to 60 days. Expedited appeals for urgent clinical situations must be resolved within 72 hours.

Alternatives If Jardiance Is Not Covered or Too Expensive

If your BCBS plan does not cover Jardiance or places it on an unaffordable tier, several clinically appropriate alternatives exist within the SGLT2 inhibitor class.

Farxiga (dapagliflozin): FDA-approved for type 2 diabetes, heart failure, and chronic kidney disease. The DAPA-HF trial (N=4,744) showed a 26% reduction in heart failure hospitalizations or cardiovascular death [11]. Some BCBS formularies place dapagliflozin on a lower (more affordable) tier than empagliflozin.

Invokana (canagliflozin): FDA-approved for type 2 diabetes and diabetic kidney disease. The CREDENCE trial (N=4,401) demonstrated a 30% relative risk reduction in the primary kidney composite endpoint [12]. Canagliflozin carries a boxed warning for increased amputation risk, which some formulary committees weigh in tier placement decisions.

Brenzavvy (bexagliflozin): A newer SGLT2 inhibitor approved in 2023 for type 2 diabetes. Limited long-term outcomes data, but it may appear on lower tiers as the manufacturer negotiates formulary positioning.

Synjardy / Synjardy XR (empagliflozin + metformin): If you need both agents, the combination tablet may have different formulary placement than standalone Jardiance. Some plans offer better coverage for combination products.

Your prescriber can also submit a formulary exception request asking the plan to cover Jardiance at a lower tier based on clinical necessity.

Checking Your Specific BCBS Coverage

The fastest way to verify your coverage is to use your BCBS affiliate's member portal. Every major BCBS affiliate maintains an online formulary search tool. Here is the process:

Log in to your BCBS member account online. Manage to the pharmacy or prescription drug benefits section. Search for "Jardiance" or "empagliflozin." The tool will display the tier, any PA or step therapy requirements, quantity limits, and estimated copay. You can also call the member services number on the back of your BCBS card and ask a representative to run a real-time pharmacy benefit check.

If you are comparing plans during open enrollment, the Centers for Medicare and Medicaid Services (CMS) Medicare Plan Finder tool at medicare.gov allows you to enter your specific medications and compare coverage across all available BCBS Medicare Advantage and Part D plans in your ZIP code [9].

For employer-sponsored BCBS plans, your human resources department can provide the Summary of Benefits and Coverage document, which includes the prescription drug tier structure and cost-sharing details.